## **Oncology Oral Medications Hematologic Malignancies Enrollment Form**



Fax Referral To: 1-888-280-1191 OR 787-759-4161

Phone: 1-888-280-1190 OR 787-759-4162

Email Referral To: customerservicefax@caremark.com

Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927

1 PATIENT INFO	ORMATIO		te or include demograp		rtolollal			
atient Name:						, State, ZIP:		
Preferred Contact Me	thods: Ph	one (to prima	ary # provided below) [	Text (to cell a	# provided below)	☐ Email (to en	nail provided below)	
Note: Carrier charges	: may apply. I	f unable to c	ontact via text or email	l, Specialty Pha	rmacy will attempt	to contact by p	hone.	
Primary Phone:		Alternate	Phone:	one:DOB:		Gender: ☐ Male ☐ Female		
mail:			Last Four of SSN	Last Four of SSN: P		rimary Language:		
PRESCRIBER	INFORM	ATION						
Prescriber's Name: _			Stat	te License #:				
NPI #:	DEA #: _		Group or Hospit	al:				
Address:			Cit	y, State, ZIP: _				
Phone:	Fa	ıx	Cit Contact l	Person:	Coi	ntact's Phone: _		
			ase fax copy of prescri					
4 DIAGNOSIS AN						,	,	
Needs by Date:	Ship to:	□ Patient [	☐ Office ☐ Other:					
Diagnosis (ICD-10):								
	Description	1		☐ Code:	Descripti	on		
			CVS Specialty Healthc			-		
			alty/healthcare-professi					
Patient Clinical Info		po. (a op oo.)						
Allergies:			Weight:	lb/ka Hei	ight:in/cm	BSA:	m²	
PRESCRIPTION				g	<b>9</b>			
Medications:	Titi Oiti	Allon				Diagnosi	e.	
						<u>Diagnosi</u>		
			ıth #: Date: ıth #: Date:					
			uth #: Date: Date:			<b>—</b>		
	-	Filysician	Autii #	Da	.e		000.10	
Pregnancy Category		otontial	☐ Adult Famala N	OT of Donrodu	etive Detential		Mala	
Adult Female – Re	•			<ul><li>☐ Adult Female – NOT of Reproductive Potentia</li><li>☐ Female Child – NOT of Reproductive Potentia</li></ul>				
Female Child – Re	productive P	otentiai	☐ Female Child – N	OT of Reprodu	ctive Potential	☐ Male (	oniid	
Medications:	- \		4: TM (	□ D	(: -  t - · · · · · · )	□ <b>-</b> 2		
Bosulif® (bosutinit	-		ti™ (moxetumomab)	•	(midostaurin)		delig® (idelalisib)	
☐ Farydak® (panobi	•		® (ixazomib)	☐ Sprycel®			her:	
☐ Gleevec® (imatinib mesylate) ☐ Pomalyst® (pomalidomide) ☐ Targretin® Capsules (						rotene)		
☐ Idhifa® (enasideni	-	•	eo® (moxetumomab)	☐ Tasigna®	` '			
Inrebic® (fedratini	•		® (mercaptopurine)		l® (thalidomide)			
☐ Jakafi® (ruxolitinib			d® (lenalidomide)		·			
PRESCRIPTIONS		ME/STRENC		IG/DIRECTION	IS		ITY/REFILLS	
RX 1	Other:		Other:			Quantity:	Refills:	
RX 2	Other:		Other:			Quantity:	Refills:	
RX 3	☐ Dexame		Other:			Quantity:	Refills:	
I hereby freely and Patient Signature:  Patient is interested	•	grams	Caremark and/or CarePlus	NOT ALLOWED	Ancillary supplie	h herein prescribed es and kits provided as ne		
							(Date)	
X				X			<del></del>	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

©2018 CVS Specialty and/or one of its affiliates. 75-35450E 092719